PL2815753T5 - Kompozycja farmaceutyczna możliwa do podawania doustnego - Google Patents

Kompozycja farmaceutyczna możliwa do podawania doustnego

Info

Publication number
PL2815753T5
PL2815753T5 PL13749171.8T PL13749171T PL2815753T5 PL 2815753 T5 PL2815753 T5 PL 2815753T5 PL 13749171 T PL13749171 T PL 13749171T PL 2815753 T5 PL2815753 T5 PL 2815753T5
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
administrable pharmaceutical
oral administrable
oral
composition
Prior art date
Application number
PL13749171.8T
Other languages
English (en)
Other versions
PL2815753T3 (pl
Inventor
Yoshito Ohnishi
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48984243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2815753(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL2815753T3 publication Critical patent/PL2815753T3/pl
Publication of PL2815753T5 publication Critical patent/PL2815753T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13749171.8T 2012-02-15 2013-02-14 Kompozycja farmaceutyczna możliwa do podawania doustnego PL2815753T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012031143 2012-02-15
EP13749171.8A EP2815753B2 (en) 2012-02-15 2013-02-14 An orally administrable pharmaceutical composition comprisinga,a,a-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4 (1h,3h)-pyrimidine dione hydrochloride
PCT/JP2013/053513 WO2013122134A1 (ja) 2012-02-15 2013-02-14 経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
PL2815753T3 PL2815753T3 (pl) 2018-10-31
PL2815753T5 true PL2815753T5 (pl) 2026-02-09

Family

ID=48984243

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13749171.8T PL2815753T5 (pl) 2012-02-15 2013-02-14 Kompozycja farmaceutyczna możliwa do podawania doustnego

Country Status (26)

Country Link
US (2) US20140356431A1 (pl)
EP (1) EP2815753B2 (pl)
JP (1) JP5798641B2 (pl)
KR (2) KR101951575B1 (pl)
CN (1) CN104105491B (pl)
AU (1) AU2013219382C1 (pl)
BR (1) BR112014018273B1 (pl)
CA (1) CA2861480C (pl)
CY (1) CY1120530T1 (pl)
DK (1) DK2815753T4 (pl)
ES (1) ES2683825T5 (pl)
FI (1) FI2815753T4 (pl)
HR (1) HRP20181193T4 (pl)
HU (1) HUE039487T2 (pl)
LT (1) LT2815753T (pl)
MX (1) MX355885B (pl)
MY (1) MY155922A (pl)
PL (1) PL2815753T5 (pl)
PT (1) PT2815753T (pl)
RS (1) RS57505B1 (pl)
RU (1) RU2600831C2 (pl)
SG (1) SG11201403874SA (pl)
SI (1) SI2815753T2 (pl)
SM (1) SMT201800415T1 (pl)
TW (1) TWI503122B (pl)
WO (1) WO2013122134A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106551946B (zh) * 2015-09-24 2020-02-14 江苏奥赛康药业有限公司 一种含三氟胸苷和盐酸替比嘧啶的药物组合物及制备方法
CN106913580A (zh) * 2015-12-27 2017-07-04 南京圣和药业股份有限公司 一种含曲氟尿苷盐酸替哌拉索的药物组合物及其应用
CN106018573B (zh) * 2016-03-16 2018-09-18 江苏悦兴药业有限公司 一种tas-102中盐酸替比拉西的纯度检测方法
CN105963271A (zh) * 2016-06-01 2016-09-28 国药心制药有限公司 一种药用辅料组合物及一种曲氟尿苷、盐酸替匹嘧啶薄膜衣片
US10866219B2 (en) * 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び/又はチピラシル由来の類縁物質の検出方法
US10816517B2 (en) * 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
WO2019171394A1 (en) 2018-03-03 2019-09-12 Natco Pharma Limited Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69629156T2 (de) 1995-03-29 2004-05-06 Taiho Pharmaceutical Co. Ltd. Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
JPH11322604A (ja) * 1998-05-06 1999-11-24 Pola Chem Ind Inc ジフェニルピペラジン化合物を含有する製剤
WO2000071117A1 (en) 1999-05-21 2000-11-30 Kissei Pharmaceutical Co., Ltd. Immediate release medicinal compositions for oral use
JP4110347B2 (ja) 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗hiv剤
JP4601934B2 (ja) * 2003-10-06 2010-12-22 ナガセ医薬品株式会社 ユビデカレノン錠
JP2005314413A (ja) * 2004-04-02 2005-11-10 Ono Pharmaceut Co Ltd 経口投与用医薬組成物
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
EP1849470B2 (en) * 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CA2649256C (en) * 2006-04-13 2013-09-10 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease
JP2007284390A (ja) * 2006-04-18 2007-11-01 Ohara Yakuhin Kogyo Kk 塩酸イミダプリル含有錠剤
RU2346684C2 (ru) * 2007-04-04 2009-02-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция на основе сигетина

Also Published As

Publication number Publication date
AU2013219382B2 (en) 2016-05-05
WO2013122134A1 (ja) 2013-08-22
JP5798641B2 (ja) 2015-10-21
US20210220384A1 (en) 2021-07-22
LT2815753T (lt) 2018-09-10
KR20170029021A (ko) 2017-03-14
RS57505B1 (sr) 2018-10-31
TW201336498A (zh) 2013-09-16
JPWO2013122134A1 (ja) 2015-05-18
RU2600831C2 (ru) 2016-10-27
SMT201800415T1 (it) 2018-09-13
SI2815753T1 (sl) 2018-11-30
FI2815753T4 (fi) 2026-02-05
EP2815753A1 (en) 2014-12-24
HRP20181193T4 (hr) 2026-03-13
PT2815753T (pt) 2018-10-08
ES2683825T3 (es) 2018-09-28
AU2013219382C1 (en) 2025-05-08
KR101951575B1 (ko) 2019-02-22
HUE039487T2 (hu) 2019-01-28
BR112014018273A8 (pt) 2017-07-11
CY1120530T1 (el) 2019-07-10
EP2815753A4 (en) 2015-07-01
SG11201403874SA (en) 2014-10-30
RU2014137096A (ru) 2016-04-10
CA2861480A1 (en) 2013-08-22
CN104105491A (zh) 2014-10-15
MY155922A (en) 2015-12-16
US20140356431A1 (en) 2014-12-04
TWI503122B (zh) 2015-10-11
DK2815753T4 (da) 2026-02-02
BR112014018273B1 (pt) 2023-04-25
DK2815753T3 (en) 2018-08-13
EP2815753B1 (en) 2018-05-16
EP2815753B2 (en) 2025-11-05
MX2014009833A (es) 2014-09-11
HRP20181193T1 (hr) 2018-10-19
HK1199822A1 (zh) 2015-07-24
CN104105491B (zh) 2016-06-15
MX355885B (es) 2018-05-02
CA2861480C (en) 2019-02-12
ES2683825T5 (en) 2026-03-19
BR112014018273A2 (pl) 2017-06-20
PL2815753T3 (pl) 2018-10-31
SI2815753T2 (sl) 2026-03-31
AU2013219382A1 (en) 2014-08-14
KR20150001717A (ko) 2015-01-06

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
AP3864A (en) Pharmaceutical composition
ZA201501930B (en) Pharmaceutical composition
ZA201503594B (en) Pharmaceutical compositions
ZA201407373B (en) Novel pharmaceutical formulations
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
SG11201403875VA (en) Oral pharmaceutical composition
SG11201403874SA (en) Oral administrable pharmaceutical composition
IL266415A (en) Innovative pharmaceutical composition
ZA201502987B (en) Pharmaceutical composition
EP2859881A4 (en) ORAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
GB201221130D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201204597D0 (en) Topical pharmaceutical formulation